Biodexa Pharmaceuticals Reports Phase 1 Clinical Data Of MTX110 In DMG Brain Cancer Demonstrating Increased Survival Presented At ISPNO 2024
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals (NASDAQ: BDRX) reported positive Phase 1 clinical data for MTX110 in treating Diffuse Midline Glioma (DMG) brain cancer, showing increased survival rates. The data was presented at ISPNO 2024, with median overall survival of 16.5 months compared to 10.0 months in historical cohorts.
July 02, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa Pharmaceuticals reported positive Phase 1 clinical data for MTX110 in DMG brain cancer, showing increased survival rates. This could boost investor confidence and potentially increase the stock price in the short term.
The positive clinical data for MTX110, showing increased survival rates in DMG brain cancer patients, is likely to boost investor confidence. Given the significant improvement in median overall survival compared to historical data, the stock price of BDRX is likely to see a positive impact in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100